Subscribe to Biological Therapies in Psychiatry -  Choose your plan >
IN THIS ISSUE:
March 2011

Vilazodone (Viibryd)
Early research suggests the newly approved antidepressant vilazodone (Viibryd) is efficacious and might cause fewer sexual side effects than other antidepressants.

Parkinson Disease and Dementia with Lewy Bodies: A Role for Memantine?
In a double-blind study, memantine (Namenda) was associated with global improvement in dementia but not cognition in patients who had dementia with Lewy bodies.

Omega-3 Fatty Acids in Depression and Pregnancy
A meta-analysis indicates that the ratio of eicosapentaenoic acid (EPA) to docosahexaenoic acid (DHA) in omega-3 polyunsaturated fatty acid supplements determines their antidepressant efficacy, while another study finds DHA supplements during pregnancy ineffective in improving postpartum depression and cognitive scores in newborns.

In Brief
Adult Attention-Deficit/Hyperactivity Disorder (ADHD) May Be Linked to Dementia with Lewy Bodies; Higher Altitude Associated with Increased Suicide Rates

Kava for Anxiety: Is It Worth It?
The modest benefits of kava for the treatment of anxiety may not be worth the risk of hepatotoxicity.

Vilazodone (Viibryd)

March 2011

On January 21, 2011, the US Food and Drug Administration approved a new drug to treat major depressive disorder (MDD): vilazodone (Viibryd). An indolealkylamine, vilazodone is a selective serotonin reuptake inhibitor (SSRI) and a partial agonist at the 5-HT1A receptor. In humans, 5-HT1A

To view the rest of this article, please: